Senior McKinsey executive shares insights on the potential contours of pharma’s 'reimagined' operations against the backdrop of COVID-19 and striking a balance between supply chain security and the cost component. A dramatic near-term shift to a “completely onshore model” in markets like the US would not realistically be possible, he indicated.
The pandemic has jolted many pharma firms into “reimagining” various aspects of their operations with technology, digitization and automation being the key operative levers to enable change across processes. Building supply chain resilience is also seen as pivotal after COVID-19 exposed crippling weaknesses in complex globalized networks.
In an interview with In Vivo, McKinsey & Company senior partner Vikas Bhadoria discussed the shape of things to come...
The EU is diversifying its trading partners, which means that new markets may open up to the pharmaceutical industry, countering transatlantic tensions.
An extensive list of blockbuster drugs face patent expiry over the next six years, putting significant revenues at risk for major companies. While Eli Lilly and Novo Nordisk are reaping the rewards of GLP-1 successes, other large pharmas face steep challenges in closing their growth gaps.
Tris Pharma may be making headlines for its novel pain medication cebranopadol, but the New Jersey-based company's story extends far beyond a single asset.
